Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics


Tenaya Therapeutics, Inc. (TNYA): $3.12

-0.12 (-3.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TNYA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TNYA Stock Price Chart Interactive Chart >

Price chart for TNYA

TNYA Price/Volume Stats

Current price $3.12 52-week high $16.17
Prev. close $3.24 52-week low $1.64
Day low $3.03 Volume 225,800
Day high $3.33 Avg. volume 278,229
50-day MA $2.36 Dividend yield N/A
200-day MA $4.57 Market Cap 129.09M

Tenaya Therapeutics, Inc. (TNYA) Company Bio


Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.


TNYA Latest News Stream


Event/Time News Detail
Loading, please wait...

TNYA Latest Social Stream


Loading social stream, please wait...

View Full TNYA Social Stream

Latest TNYA News From Around the Web

Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.

Tenaya Therapeutics up 6% following director stock purchase

  • Tenaya Therapeutics (NASDAQ:TNYA) is up ~6% in after-hours trading on Thursday after a member of the board of directors made a large acquisition of additional shares.
  • David Goeddel, managing partner at The Column Group, bought 49,463 shares on Jan. 17 at an average price of $2.49 per share, and another 135,688 shares on Jan. 18 at an average $2.52 per share.
  • The shares are directly held by The Column Group, who in total own ~5M shares, according to a Seeking Alpha | January 19, 2023

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended into First Half 2025 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and

Yahoo | January 9, 2023

Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop

The recent price decline of 23% in Tenaya Therapeutics, Inc.'s ( NASDAQ:TNYA ) stock may have disappointed insiders who...

Yahoo | December 21, 2022

Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock?

In last trading session, Tenaya Therapeutics Inc. (NASDAQ:TNYA) saw 0.49 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.30 trading at -$0.07 or -2.95% at ring of the bell on the day assigns it a market valuation of $158.93M. That closing price of TNYA’s stock is … Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock? Read More »

Marketing Sentinel | December 17, 2022

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases.

GlobeNewswire | December 7, 2022

Read More 'TNYA' Stories Here

TNYA Price Returns

1-mo 85.71%
3-mo 9.09%
6-mo -34.59%
1-year -69.68%
3-year N/A
5-year N/A
YTD 55.22%
2022 -89.39%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7196 seconds.